Oral NA-931

# FOR THE TREATMENT OF OBESITY

## Contact for Partnering Opportunities


Michael Willis
VP, Business Development
Biomed Industries, Inc.

2570 N. First Street, 2nd Floor,
San Jose, CA 95131

**PHONE**
+1-800-824-5135

**WEBSITE**
www.biomedind.com

**EMAIL**
mwillis@biomedind.com

# EXECUTIVE SUMMARY

## COMPANY OVERVIEW

***Advancing Breakthrough Oral Therapies for Obesity and Metabolic Disorders***

Biomed Industries™, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics to address major unmet medical needs. With over two decades of success in neurodegenerative drug development, Biomed has identified key mechanistic links between metabolic dysfunction and neurological disease—insights that have driven the development of NA-931™, a novel oral therapy for obesity.

## THE CHALLENGE

Current obesity treatments—primarily injectables targeting single, dual, or triple incretin receptors—are often associated with significant drawbacks including inconvenient administration, high cost, and frequent adverse events. These limitations restrict access and long-term adherence, particularly among underserved populations.

## INTRODUCING NA-931™

NA-931 is a first-in-class, oral small-molecule quadruple receptor agonist that simultaneously targets IGF-1, GLP-1, GIP, and Glucagon receptors. This multi-pathway approach restores metabolic homeostasis and drives clinically meaningful weight loss—without muscle loss or severe side effects.

## KEY ADVANTAGES OF NA-931™

- Oral, once-daily dosing for improved patient adherence
- Excellent bioavailability and CNS penetration
- No serious adverse events reported in trials
- Cost-effective alternative to GLP-1 injectable drugs
- Broad applicability across obesity, metabolic syndrome, and T2DM

# Phase 1 Clinical Results

### DESIGN:

A randomized, double-blind, placebo-controlled multiple ascending dose (MAD) study followed by an 8-week open-label extension (total 12 weeks) in overweight and obese participants, including individuals with type 2 diabetes.

### EFFICACY:

- **28 days:** Mean weight loss of 6.8%, or 5.1% greater than placebo ($p < 0.001$)
- **12 weeks:** At 150 mg/day, weight loss reached 12.7%, or 10.4% greater than placebo

### SAFETY:

- **28-Day:** 86% of adverse events were rated as insignificant; mild nausea in 8.3% at 150 mg/day; no vomiting
- **12 weeks:** 78% of TEAEs were mild or insignificant; mild nausea in 16.6%; no vomiting, low incidence of diarrhea

### PHARMACOKINETICS:

- Stable PK profile across doses
- No food effect, allowing flexible dosing schedule

# Phase 2 Topline Results

NA-931 completed Phase 2 in April 2025. Results reaffirm the strong efficacy and safety seen in Phase 1 and will be presented at the American Diabetes Association (ADA) Scientific Sessions on June 20, 2025. Data remain confidential and are available under CDA.

### Press release:

Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025 Conference

***https://biomedind.com/news-NA-931-Phase2-ADA.html***